TEH-TUBE

Tissue engineering of the right heart outflow tract by a biofunctionalized bioresorbable polymeric valved tube

Coordinatore	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS    more  Organization address address: 3 Avenue Victoria city: PARIS postcode: 75004 contact info Titolo: Mrs. Nome: Patricia Cognome: Schott Email: send email Telefono: 33140274613 Fax: 33144841703
Nazionalità Coordinatore	France [FR]
Sito del progetto	http://www.teh-tube.eu
Totale costo	5˙744˙057 €
EC contributo	4˙500˙962 €
Programma	FP7-NMP Specific Programme "Cooperation": Nanosciences, Nanotechnologies, Materials and new Production Technologies
Code Call	FP7-NMP-2013-SME-7
Funding Scheme	CP-TP
Anno di inizio	2014
Periodo (anno-mese-giorno)	2014-01-01   -   2017-12-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS  Organization address address: 3 Avenue Victoria city: PARIS postcode: 75004 contact info Titolo: Mrs. Nome: Patricia Cognome: Schott Email: send email Telefono: 33140274613 Fax: 33144841703	FR (PARIS)	coordinator	765˙880.00
2	CARDIO3 BIOSCIENCES SA  Organization address address: RUE EDOUARD BELIN 12 city: MONT SAINT GUIBERT postcode: 1435 contact info Titolo: Mr. Nome: Aymeric Cognome: Seron Email: send email Telefono: 3210394147 Fax: 3210394141	BE (MONT SAINT GUIBERT)	participant	948˙060.00
3	HELMHOLTZ-ZENTRUM GEESTHACHT ZENTRUM FUR MATERIAL- UND KUSTENFORSCHUNG GMBH  Organization address address: Max-Planck-Strasse 1 city: GEESTHACHT postcode: 21502 contact info Titolo: Dr. Nome: Hans-Jörg Cognome: Isemer Email: send email Telefono: +49 4152 871661 Fax: +49 4152 871730	DE (GEESTHACHT)	participant	748˙034.00
4	STATICE SAS  Organization address address: RUE THOMAS EDISON 9 city: BESANCON postcode: 25000 contact info Titolo: Ms. Nome: Anne Cognome: Legain Email: send email Telefono: +33 381 48 48 73 Fax: +33 381 53 35 23	FR (BESANCON)	participant	739˙902.00
5	RESCOLL  Organization address address: ALLEE GEOFFROY SAINT HILAIRE 8 city: PESSAC postcode: 33600 contact info Titolo: Mr. Nome: Konstantin Cognome: Sipos Email: send email Telefono: +33 547746900	FR (PESSAC)	participant	676˙860.00
6	UNIVERSITY COLLEGE LONDON  Organization address address: GOWER STREET city: LONDON postcode: WC1E 6BT contact info Titolo: Ms. Nome: Kamila Cognome: Kolasinska Email: send email Telefono: +44 2031083033 Fax: +44 20 78132849	UK (LONDON)	participant	368˙466.00
7	EURAM LIMITED  Organization address address: "Tower House, Lucy Tower Street" city: LINCOLN postcode: LN1 1XW contact info Titolo: Mr. Nome: Andrew Cognome: Banasik Email: send email Telefono: +44 1159811335 Fax: +44 1159541295	UK (LINCOLN)	participant	253˙760.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Approximately 42% of infants’ mortality in the world is related to congenital heart defects (prevalence: 8-12/1000 births). Over 1/3 require the reconstruction of the right ventricular outflow tract (RVOT) by surgical procedures which currently use inert materials without any growth potential. Consequently, multiple reoperations are often required, with their attendant high risk of mortality and morbidity. The TEH-TUBE project will address these limitations by creating a novel bioabsorbable biomaterial using a polymeric valved tube either seeded with autologous adipose tissue derived stem cells (ADSC) or functionalized by a peptidic sequence triggering homing of the host cells onto the scaffold to make it a living self-populated structure. During the project we will: • Compare 3 different polymers (polydioxanone, polyhydroxyalkanoate, poly-ester-urethane-ureas) processed by electrospinning to generate a competent valved tube • Compare, in the selected polymer, ADSC seeding and peptide grafting using in vitro mechanical and biological tests as well as in vivo animal experiments (primarily rats) • Validate the ultimate combination (polymer cells or peptides) in a clinically relevant large animal model (in this case, the growing lamb to specifically assess the regenerative and growth potential of the composite construct) This stepwise approach will be conducted within a tightly controlled regulatory framework to ensure that the final product meets the current ATMP requirements for phase I/II clinical studies and, if successful, ultimate commercialization. Our TEH-TUBE project aims at developing an innovative biomaterial for the treatment of congenital heart abnormalities in children and young adults. By creating a material whose growth will keep pace with that of the patient, this product, geared to become an ATMP, should decrease the risk of reoperative surgeries, improve the quality of life and ultimately have a positive impact on healthcare costs.'